|  |
Investors & Media Investor Relations Home| The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax® (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex® (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desi... More >> | |
 |
| Date | Title | | | 06/30/09 | The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635| PARSIPPANY, NJ, Jun 30, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that in
accordance with NASDAQ Marketplace Rule 5635, the Company issued new
inducement stock options to one new hire due to additional hiring in
connection with its global expansion.
The inducement stock options covers 1,000 shares of common stock and
are classified as non-qualified stock options with an exercise price
equal to the fair market value on the grant date. The options h... |
|  | | 06/19/09 | FDA Grants The Medicines Company Pediatric Exclusivity for Angiomax(R)| Prospective Study Demonstrates Safety and Predictability of Angiomax in the Pediatric PopulationPARSIPPANY, NJ, Jun 19, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that the U.S.
Food and Drug Administration (FDA) has granted pediatric exclusivity
for Angiomax(R) (bivalirudin), based on studies submitted in response
to a Written Request by the FDA to investigate the use of Angiomax in
pediatric patients aged birth to 16-years old. With this additional
... |
| | | 06/16/09 | The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635| PARSIPPANY, NJ, Jun 16, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that in
accordance with NASDAQ Marketplace Rule 5635, the Company issued new
inducement stock options to 12 new hires due to additional hiring in
connection with its global expansion.
The inducement stock options covers 26,000 shares of common stock and
are classified as non-qualified stock options with an exercise price
equal to the fair market value on the grant date. The options ... |
| | | 06/01/09 | The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 4350| PARSIPPANY, NJ, Jun 01, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that in
accordance with NASDAQ Marketplace Rule 4350, the Company issued new
inducement stock options to two executive and non-executive new hires
due to additional hiring in connection with its global expansion.
The inducement stock options covers 4,000 shares of common stock and
are classified as non-qualified stock options with an exercise price
equal to the fair market value on ... |
| |
|
|
| There are currently no events scheduled. |
Receive E-mail Alerts | | Sign up to receive e-mail alerts whenever The Medicines Company posts new information to the site. Just enter your e-mail address and click Submit. |
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
|
|
|
